SEATTLE--(BUSINESS WIRE)--Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, announced today that interim clinical data from the company’s Phase 1 study of Tumor Paint BLZ-100 in adult patients with brain cancer will be presented at the 20th Annual Society for Neuro-Oncology (SNO) Scientific Meeting to be held November 19-22, 2015 in San Antonio, Texas.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
